Back in July, it looked like Transcept Pharmaceutical Inc.'s insomnia drug Intermezzo (zolpidem tartrate) was down for the count. The company, aiming to provide the first treatment specifically for middle-of-the-night waking, had just gotten a surprise second complete response letter (CRL), despite conducting the FDA-requested next-day highway driving study.